Head-To-Head Survey: Cerevel Therapeutics (NASDAQ:CERE) vs. JanOne (NASDAQ:JAN)

JanOne (NASDAQ:JAN) and Cerevel Therapeutics (NASDAQ:CERE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Insider and Institutional Ownership

6.3% of JanOne shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 3.0% of JanOne shares are held by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares JanOne and Cerevel Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JanOne	N/A	-359.71%	-70.26%
Cerevel Therapeutics	N/A	-98.94%	-45.07%

Volatility and Risk

JanOne has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for JanOne and Cerevel Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JanOne	0	0	0	0	N/A
Cerevel Therapeutics	0	7	1	0	2.13

Cerevel Therapeutics has a consensus target price of $44.13, suggesting a potential downside of 1.86%.

Earnings and Valuation

This table compares JanOne and Cerevel Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JanOne	$39.61 million	0.00	-$7.81 million	N/A	N/A
Cerevel Therapeutics	N/A	N/A	-$432.84 million	($2.73)	-16.47

JanOne has higher revenue and earnings than Cerevel Therapeutics.

Summary

Cerevel Therapeutics beats JanOne on 5 of the 8 factors compared between the two stocks.

About JanOne

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.